# Christopher G Parsons

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 75 papers | 4,945 citations | 117619 34 h-index | 88628 70 g-index |
| 76 all docs | 76 docs citations | 76 times ranked | 5320 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Inhalational Anesthetics Do Not Deteriorate Amyloid-Î²-Derived Pathophysiology in Alzheimerâ€™s Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. Journal of Alzheimer's Disease, 2021, 84, 1193-1218. | 2.6 | 1 |
| 2 | The AÎ² aggregation modulator MRZ-99030 prevents and even reverses synaptotoxic effects of AÎ²1-42 on LTP even following serial dilution to a 500:1 stoichiometric excess of AÎ²1-42, suggesting a beneficial prion-like seeding mechanism. Neuropharmacology, 2020, 179, 108267. | 4.1 | 5 |
| 3 | The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity. Neuropharmacology, 2019, 151, 21-32. | 4.1 | 7 |
| 4 | CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity. Neuropharmacology, 2019, 147, 4-10. | 4.1 | 17 |
| 5 | The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (AÎ²) species on long-term potentiation (LTP). Neuropharmacology, 2018, 140, 184-192. | 4.1 | 22 |
| 6 | Involvement of GluN2B subunit containing N-methyl- d -aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (AÎ²) in murine models of Alzheimer's disease (AD). Neuropharmacology, 2017, 123, 100-115. | 4.1 | 29 |
| 7 | Preclinical to phase II amyloid beta (A<sub>Î²</sub>) peptide modulators under investigation for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2017, 26, 579-592. | 4.1 | 23 |
| 8 | MRZ-99030 â€“ A novel modulator of AÎ² aggregation: II â€“ Reversal ofÂAÎ² oligomer-induced deficits in long-term potentiation (LTP) andÂcognitive performance in rats and mice. Neuropharmacology, 2015, 92, 170-182. | 4.1 | 23 |
| 9 | MRZ-99030 â€“ A novel modulator of AÎ² aggregation: I â€“ Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD). Neuropharmacology, 2015, 92, 158-169. | 4.1 | 27 |
| 10 | Effects of sarizotan in animal models of ADHD: challenging pharmacokineticâ€“pharmacodynamic relationships. Journal of Neural Transmission, 2015, 122, 1221-1238. | 2.8 | 3 |
| 11 | Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy â€“ Comparison to MPEP. Pharmacological Reports, 2015, 67, 624-630. | 3.3 | 9 |
| 12 | Patch Clamp Combined with Voltage/Concentration Clamp to Determine the Kinetics and Voltage Dependency of N-Methyl-d-aspartate (NMDA) Receptor Open Channel Blockers. Methods in Molecular Biology, 2014, 1183, 43-63. | 0.9 | 1 |
| 13 | Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimerâ€™s Disease. Neurotoxicity Research, 2013, 24, 358-369. | 2.7 | 246 |
| 14 | Preparation and testing of homocubyl amines as therapeutic NMDA receptor antagonists. Medicinal Chemistry Research, 2013, 22, 360-366. | 2.4 | 25 |
| 15 | Lipid raft integrity affects GABAA receptor, but not NMDA receptor modulation by psychopharmacological compounds. International Journal of Neuropsychopharmacology, 2013, 16, 1361-1371. | 2.1 | 29 |
| 16 | GluN2A and GluN2B NMDA Receptor Subunits Differentially Modulate Striatal Output Pathways and Contribute to Levodopa-Induced Abnormal Involuntary Movements in Dyskinetic Rats. ACS Chemical Neuroscience, 2013, 4, 808-816. | 3.5 | 13 |
| 17 | Assessment of the effects of NS11394 and L-838417, Î±2/3 subunit-selective GABAA receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function. Behavioural Pharmacology, 2012, 23, 790-801. | 1.7 | 17 |
| 18 | Alzheimer's disease, Î²â€amyloid, glutamate, NMDA receptors and memantine â€“ searching for the connections. British Journal of Pharmacology, 2012, 167, 324-352. | 5.4 | 396 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimerâ€™s disease. Expert Review of Neurotherapeutics, 2012, 12, 1351-1365. | 2.8 | 39 |
| 20 | Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of Î²-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology, 2011, 60, 982-990. | 4.1 | 141 |
| 21 | Synthesis of a series of Î³-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5795-5799. | 2.2 | 16 |
| 22 | Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on l-DOPA-induced dyskinesia. Journal of Neural Transmission, 2011, 118, 1703-1716. | 2.8 | 25 |
| 23 | In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons. Journal of Neural Transmission, 2010, 117, 1189-1194. | 2.8 | 9 |
| 24 | Memantine Improves Cognition and Reduces Alzheimerâ€™s-Like Neuropathology in Transgenic Mice. American Journal of Pathology, 2010, 176, 870-880. | 3.8 | 188 |
| 25 | Synergism of virtual screening and medicinal chemistry: Identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1. Bioorganic and Medicinal Chemistry, 2009, 17, 5708-5715. | 3.0 | 25 |
| 26 | Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors. Neuropharmacology, 2009, 56, 866-875. | 4.1 | 63 |
| 27 | Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes. Journal of Neural Transmission, 2008, 115, 1367-1373. | 2.8 | 6 |
| 28 | Memantine does not show intracellular block of the NMDA receptor channel. European Journal of Pharmacology, 2008, 587, 99-103. | 3.5 | 16 |
| 29 | Positive and Negative Modulation of Group I Metabotropic Glutamate Receptors. Journal of Medicinal Chemistry, 2008, 51, 634-647. | 6.4 | 49 |
| 30 | Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-d-aspartate receptors by memantine. Neuropharmacology, 2007, 53, 415-420. | 4.1 | 22 |
| 31 | Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse. Neuropharmacology, 2007, 53, 699-723. | 4.1 | 593 |
| 32 | Memantine as an Example of a Fast, Voltage-Dependent, Open Channel N-Methyl-d-Aspartate Receptor Blocker. Methods in Molecular Biology, 2007, 403, 15-36. | 0.9 | 36 |
| 33 | Searching for Drug Scaffolds with 3D Pharmacophores and Neural Network Ensembles. Angewandte Chemie - International Edition, 2007, 46, 5336-5339. | 13.8 | 21 |
| 34 | Virtual Screening for Selective Allosteric mGluR1 Antagonists and Structureâ€“Activity Relationship Investigations for Coumarine Derivatives. ChemMedChem, 2007, 2, 1763-1773. | 3.2 | 34 |
| 35 | Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo. European Journal of Pharmacology, 2007, 554, 18-29. | 3.5 | 41 |
| 36 | Inhibition of the Î±9Î±10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-d-aspartate receptors. European Journal of Pharmacology, 2007, 566, 11-19. | 3.5 | 31 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy. Neuropharmacology, 2006, 50, 1006-1015. | 4.1 | 27 |
| 38 | The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism. Neuropharmacology, 2006, 51, 12-17. | 4.1 | 43 |
| 39 | Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behavioural Pharmacology, 2006, 17, 411-424. | 1.7 | 118 |
| 40 | Predicting Compound Selectivity by Self-Organizing Maps: Cross-Activities of Metabotropic Glutamate Receptor Antagonists. ChemMedChem, 2006, 1, 1066-1068. | 3.2 | 54 |
| 41 | 3-Nitropropionic acid toxicity in hippocampus: Protection throughN-methyl-D-aspartate receptor antagonism. Hippocampus, 2006, 16, 834-842. | 1.9 | 33 |
| 42 | New Allosteric Modulators of Metabotropic Glutamate Receptor 5 (mGluR5) Found by Ligand-Based Virtual Screening. ChemBioChem, 2005, 6, 620-625. | 2.6 | 26 |
| 43 | Peripherally acting NMDA receptor/glycine site receptor antagonists inhibit morphine tolerance. Neuropharmacology, 2005, 48, 360-371. | 4.1 | 22 |
| 44 | N-Methyl-d-Aspartate Receptors Mediate Endogenous Opioid Release in Enteric Neurons After Abdominal Surgery. Gastroenterology, 2005, 128, 2009-2019. | 1.3 | 28 |
| 45 | Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-175. | 4.1 | 0 |
| 46 | Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain. Neuropharmacology, 2004, 47, 175-183. | 4.1 | 35 |
| 47 | Chronic memantine does not block 3-nitropropionic acid-delayed ischaemic tolerance in rat hippocampal slicesex vivo. Neurotoxicity Research, 2003, 5, 617-22. | 2.7 | 5 |
| 48 | Are neuronal nicotinic receptors a target for antiepileptic drug development? Studies in different seizure models in mice and rats. European Journal of Pharmacology, 2003, 466, 99-111. | 3.5 | 36 |
| 49 | The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. International Journal of Geriatric Psychiatry, 2003, 18, S23-S32. | 2.7 | 327 |
| 50 | Expression of Polyglutamine-expanded Huntingtin Induces Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors. Journal of Biological Chemistry, 2003, 278, 33364-33369. | 3.4 | 79 |
| 51 | Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotoxicity Research, 2002, 4, 119-126. | 2.7 | 42 |
| 52 | Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain, 2001, 91, 201-207. | 4.2 | 19 |
| 53 | NMDA receptors as targets for drug action in neuropathic pain. European Journal of Pharmacology, 2001, 429, 71-78. | 3.5 | 210 |
| 54 | Neuroprotective and symptomatological action of memantine relevant for alzheimerâ€™s disease â€” a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Research, 2000, 2, 85-97. | 2.7 | 211 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Differential effects of NMDAâ€“receptor antagonists on long-term potentiation and hypoxic/hypoglycaemic excitotoxicity in hippocampal slices. Neuropharmacology, 2000, 39, 631-642. | 4.1 | 31 |
| 56 | Expression of early hippocampal CA1 LTP does not lead to changes in AMPA-EPSC kinetics or sensitivity to cyclothiazide. Pflugers Archiv European Journal of Physiology, 1999, 437, 191-196. | 2.8 | 14 |
| 57 | Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: in vitro and in vivo characterization. Neuropharmacology, 1999, 38, 85-108. | 4.1 | 130 |
| 58 | Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ In hippocampal slices. Neuropharmacology, 1999, 38, 1253-1259. | 4.1 | 102 |
| 59 | Electrophysiological Study, Biodistribution in Mice, and Preliminary PET Evaluation in a Rhesus Monkey of 1-Amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): A Potential Radioligand for Mapping the NMDA-Receptor Complex. Nuclear Medicine and Biology, 1998, 25, 323-330. | 0.6 | 41 |
| 60 | Budipine is a low affinity, N-methyl-d-aspartate receptor antagonist: patch clamp studies in cultured striatal, hippocampal, cortical and superior colliculus neurones. Neuropharmacology, 1998, 37, 719-727. | 4.1 | 21 |
| 61 | Interactions of GYKI 52466 and NBQX with cyclothiazide at AMPA receptors: experiments with outside-out patches and EPSCs in hippocampal neurones. Neuropharmacology, 1998, 37, 1299-1320. | 4.1 | 32 |
| 62 | Effects of memantine and MKâ€801 on NMDAâ€induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. British Journal of Pharmacology, 1996, 117, 689-697. | 5.4 | 119 |
| 63 | Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. British Journal of Pharmacology, 1996, 119, 195-204. | 5.4 | 90 |
| 64 | Interactions of 2,3â€benzodiazepines and cydothiazide at AMPA receptors: patch clamp recordings in cultured neurones and area CA1 in hippocampal slices. British Journal of Pharmacology, 1996, 117, 1209-1221. | 5.4 | 47 |
| 65 | Zinc changes AMPA receptor properties: Results of binding studies and patch clamp recordings. Neuropharmacology, 1996, 35, 503-509. | 4.1 | 42 |
| 66 | Learning deficits induced by chronic intraventricular infusion of quinolinic acid â€" protection by MK-801 and memantine. European Journal of Pharmacology, 1996, 296, 1-8. | 3.5 | 88 |
| 67 | Effects of the Uncompetitive NMDA Receptor Antagonist Memantine on Hippocampal Long-term Potentiation, Short-term Exploratory Modulation and Spatial Memory in Awake, Freely Moving Rats. European Journal of Neuroscience, 1996, 8, 565-571. | 2.6 | 134 |
| 68 | Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo. Neuroscience Letters, 1994, 165, 37-40. | 2.1 | 28 |
| 69 | Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology, 1993, 32, 1337-1350. | 4.1 | 271 |
| 70 | Whole cell and single channel analysis of the kinetics of glycineâ€sensitive Nâ€methylâ€Dâ€aspartate receptor desensitization. British Journal of Pharmacology, 1993, 109, 213-221. | 5.4 | 37 |
| 71 | Effects of intravenous Î¼ and Î¹ opioid receptor agonists on sensory responses of convergent neurones in the dorsal horn of spinalized rats. British Journal of Pharmacology, 1991, 103, 1230-1236. | 5.4 | 14 |
| 72 | Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. Pain, 1990, 41, 81-93. | 4.2 | 61 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Spinal antinociceptive actions of Î¼â€•and Îºâ€•opioids: the importance of stimulus intensity in determining â€˜selectivityâ€™ between reflexes to different modalities of noxious stimulus. British Journal of Pharmacology, 1989, 98, 523-532. | 5.4 | 42 |
| 74 | Spinal antinociceptive actions and naloxone reversibility of intravenous Î¼â€•and Îºâ€•opioids in spinalized rats: potency mismatch with values reported for spinal administration. British Journal of Pharmacology, 1989, 98, 533-543. | 5.4 | 27 |
| 75 | On the selectivity of intravenous Î¼- and Îº-opioids between nociceptive and non-nociceptive reflexes in the spinalized rat. British Journal of Pharmacology, 1989, 98, 544-551. | 5.4 | 9 |